中英文簡介
瑞陽公司始建于1966年,是一家集研發(fā)、生產(chǎn)、銷售于一體的現(xiàn)代化制藥企業(yè)。公司年銷售收入70余億元，綜合實力位居中國醫(yī)藥工業(yè)企業(yè)排行榜前50強。
公司占地面積100萬平方米，設(shè)有三個廠區(qū)，建有粉針（凍干粉針）制劑類、無菌原料藥類、固體制劑類和中藥制劑類等30多個生產(chǎn)車間，且均通過了中國國家藥品GMP認(rèn)證。年產(chǎn)粉針（含凍干）劑25億瓶、小容量注射劑3億支、片劑40億片、膠囊劑60億粒、顆粒劑2億袋、栓劑1000萬粒、無菌原料藥2000噸。公司還通過了IS09001、ISO14001和OHS18001國際質(zhì)量、環(huán)境、職業(yè)健康安全管理體系認(rèn)證。
多年來，公司堅持以創(chuàng)新驅(qū)動發(fā)展，先后在北京、上海、蘇州、濟南以及美國設(shè)立了研發(fā)中心，主要圍繞心腦血管類、呼吸系統(tǒng)、**系統(tǒng)以及抗腫瘤藥物等領(lǐng)域，開展新藥研發(fā)工作。公司在研產(chǎn)品有160多個，其中有52個品種已經(jīng)上報生產(chǎn)，有18個品種已獲得臨床批件，有36個品種已上報臨床。新產(chǎn)品的陸續(xù)上市將進(jìn)一步增強公司的競爭力。
目前，瑞陽公司的產(chǎn)品已覆蓋中國各地，并且在全球60多個國家獲得了認(rèn)可。公司產(chǎn)品出口額6億元，制劑出口位列中國前五強。隨著國際認(rèn)證步伐的推進(jìn)，公司產(chǎn)品將逐漸銷往歐美等地區(qū)，公司的國際化水平將進(jìn)一步提升。
展望未來，隨著新產(chǎn)品陸續(xù)上市，瑞陽公司的產(chǎn)品結(jié)構(gòu)將日益完善，生產(chǎn)水平和市場掌控能力將進(jìn)一步提升，瑞陽公司將會提供一個更廣闊的合作平臺，與各位朋友攜手并進(jìn)、共謀發(fā)展。
Reyoung Pharma was founded in 1966 and has emerged as an integrated modern pharmaceutical enterprise specializing in the R＆D, production and distribution of pharmaceutical products. With an annual sales volume of more than 7 billion RMB, Reyoung was ranked among the top 50 of all the Chinese Pharmaceutical Enterprises. `
It covers an area of more than 1 million square meters, including 3 factories, and has built 30 workshops including powder for injection workshops (lyophilized), API workshops, solid preparation workshops and traditional Chinese medicine workshops etc. And all of these workshops passed the Chinese national drug GMP certification. The annual output for powder for injections (including lyophilized powder for injections) achieves 2.5 billion vials, small volume injections 300 million ampoules, tablets 4 billion tabs, capsules 6 billion caps, granules 200 million bags, suppository 10 million grains, API 2,000 tons. And Reyoung also passed the IS09001, ISO14001 and OHS18001 international quality, environmental, occupational health and safety management system certification.
Reyoung is sticking to the innovation-driven development for many years, and set R&D centers in Beijing, Shanghai, Suzhou, Jinan and USA successively, mainly focuses on the fields of Cardio-cerebrovascular, respiratory system, nervous & mental system, and antineoplastic drugs, to develop and research on that. Now there are more than one hundred and sixty products are under research, and of which more than fifty two has applied for production, and eighteen has got clinical trial permission, and thirty six has been applied for clinical trial. The entering into the market successively of the new products will strengthen the competitiveness of our company.
Now the products of Reyoung have covered the whole market of China, and has been successfully approved and marketed in more than 60 countries all over the world. The sales income of export in 2015 is 600 million RMB, and was ranked the top 5 among all the formulation export manufacturers and companies in China. As the promotion of the international certifications, our goods will be marketed to European countries and USA soon, the internationalization level will be improved further.
Look into the future, as the entering into the market successively of the new products, the product structure of Reyoung will be improved, the producing levels and the market-controlling power will be enhanced further, and Reyoung will provide a wider platform for our old and new friends to go hand in hand and seek common development.
